Investor Alert: Argentina Loaded With "White Gold" Opportunity
Experts expect the global lithium market to grow by 500% due to the explosion of electric vehicles and green energy. And one small-cap company just snagged a large lithium deposit in a renowned South American location.
Read about this once-in-a-lifetime opportunity
Shreeram Aradhye, insider at Dicerna Pharmaceuticals
Shreeram Aradhye Insider Alerts

Get notified the next time Shreeram Aradhye buys or sells Dicerna Pharmaceuticals stock. Enter your email address below to get our daily insider buying and selling report.

Shreeram Aradhye Insider Information

Shreeram Aradhye, M.D., joined Dicerna in September 2020 from Axcella Health where he served as Executive Vice President and Chief Development Officer overseeing clinical development, regulatory affairs, quality assurance and scientific communications. 

Prior to joining Axcella, Dr. Aradhye served for over two decades at Novartis Pharmaceuticals in multiple leadership roles of increasing responsibility in drug development and medical affairs, and across multiple therapeutic areas and geographies. In his most recent role as Chief Medical Officer of Novartis, he was a member of the Global Pharmaceuticals Executive Committee responsible for over $20 billion in worldwide business, providing medical expertise on portfolio strategy and leading governance of medical activities worldwide. Dr. Aradhye was also a member of the development committee of Novartis that oversaw global development activities across its portfolio. In previous roles at Novartis and Sandoz, he led the clinical development program for Gilenya® in multiple sclerosis (MS), provided functional leadership for clinical development and medical affairs teams working on novel and biosimilar medicines across multiple therapeutic areas, and headed global development for neuroscience, where he oversaw a portfolio of programs in MS, Alzheimer’s Disease, neuropathic pain, muscle disease and migraine.

Prior to industry, Dr. Aradhye was Assistant Professor of Medicine and a transplant nephrologist at the University of Pennsylvania. Dr. Aradhye received his medical education at the All India Institute of Medical Sciences in New Delhi, India, and in Internal Medicine and Nephrology in the United States.

How do I contact Shreeram Aradhye?

The corporate mailing address for Dr. Aradhye and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at (617) 621-8097 and via email at [email protected]

Has Shreeram Aradhye been buying or selling shares of Dicerna Pharmaceuticals?

Shreeram Aradhye has not been actively trading shares of Dicerna Pharmaceuticals in the last ninety days. Most recently, Shreeram Aradhye sold 2,056 shares of the business's stock in a transaction on Friday, September 17th. The shares were sold at an average price of $21.47, for a transaction totalling $44,142.32.

Who are Dicerna Pharmaceuticals' active insiders?

Dicerna Pharmaceuticals' insider roster includes Shreeram Aradhye (EVP), Bob Brown (EVP), Robert Ciappenelli (Insider), Douglas Fambrough (CEO), Marc Kozin (Director), Regina Paglia (Insider), James Weissman (COO), and Ling Zeng (Insider).

Are insiders buying or selling shares of Dicerna Pharmaceuticals?

In the last year, Dicerna Pharmaceuticals insiders bought shares 2 times. They purchased a total of 8,000 shares worth more than $181,480.00. In the last year, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 1,277,035 shares worth more than $32,649,559.26. The most recent insider tranaction occured on November, 18th when EVP Bob D Brown sold 24,936 shares worth more than $946,071.84. Insiders at Dicerna Pharmaceuticals own 10.2 % of the company.

Information on this page was last updated on 11/18/2021.

Shreeram Aradhye Insider Trading History at Dicerna Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2021Sell2,056$21.47$44,142.32View SEC Filing Icon  
See Full Table

Shreeram Aradhye Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows Shreeram Aradhye's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $38.08
Low: $37.96
High: $38.13

50 Day Range

MA: $23.73
Low: $19.26
High: $38.08

2 Week Range

Now: $38.08
Low: $19.06
High: $40.14

Volume

10,487,528 shs

Average Volume

4,377,718 shs

Market Capitalization

$2.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93
Health Stock on the Rise
This stock could be a major success story in 2021.
Here's why.